Payment overview · 2025
General Payments
$570.89
41 reported records · 9 companies
Healthcare provider profile · identity verified
Kyle R. Speakman, MD
Allopathic & Osteopathic Physicians|Family Medicine · MARION, IN · NPI 1104269240
Verified facts
What the public records show
CMS Open Payments records show Kyle R. Speakman, MD received $570.89 in general payments during 2025 across 41 reported records.
ABBVIE INC. accounted for 27.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 124 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $155.38 | 27.2% | 15 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $149.58 | 26.2% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $142.11 | 24.9% | 10 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $38.64 | 6.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.71 | 4.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.60 | 3.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.28 | 2.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $13.93 | 2.4% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $13.66 | 2.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $570.89 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $149.58 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.32 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $88.32 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $81.29 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $67.06 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $61.91 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $44.98 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $38.64 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $35.60 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $23.71 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $13.93 | 1 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $13.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 124 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
105 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
73 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
124 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 872 | 256 |
| Lisinopril | Lisinopril | 471 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 391 | 117 |
| Omeprazole | Omeprazole | 360 | 109 |
| Metformin Hcl | Metformin Hcl | 337 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 273 | 78 |
| Gabapentin | Gabapentin | 264 | 81 |
| Furosemide | Furosemide | 251 | 80 |
| Meloxicam | Meloxicam | 230 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 226 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 218 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 211 | 66 |
| Losartan Potassium | Losartan Potassium | 207 | 69 |
| Escitalopram Oxalate | Escitalopram Oxalate | 175 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 48 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 36 |
| Trazodone Hcl | Trazodone Hcl | 135 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 133 | 39 |
| Buspirone Hcl | Buspirone Hcl | 132 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 129 | 50 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 35 |
| Eliquis | Apixaban | 124 | 37 |
| Glimepiride | Glimepiride | 115 | 31 |
| Potassium Chloride | Potassium Chloride | 115 | 38 |
| Simvastatin | Simvastatin | 115 | 31 |
| Tramadol Hcl | Tramadol Hcl | 113 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 35 |
| Carvedilol | Carvedilol | 110 | 39 |
| Montelukast Sodium | Montelukast Sodium | 110 | 32 |
| Sertraline Hcl | Sertraline Hcl | 107 | 31 |
| Jardiance | Empagliflozin | 105 | 30 |
| Januvia | Sitagliptin Phosphate | 101 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 27 |
| Famotidine | Famotidine | 93 | 25 |
| Allopurinol | Allopurinol | 91 | 29 |
| Spironolactone | Spironolactone | 90 | 28 |
| Bupropion Xl | Bupropion Hcl | 83 | 21 |
| Metformin Hcl Er | Metformin Hcl | 83 | 24 |
| Alendronate Sodium | Alendronate Sodium | 82 | 23 |
| Diclofenac Sodium | Diclofenac Sodium | 77 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 19 |
| Alprazolam | Alprazolam | 73 | 15 |
| Ozempic | Semaglutide | 73 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 19 |
| Ezetimibe | Ezetimibe | 67 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 17 |
| Pregabalin | Pregabalin | 59 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 52 | 12 |
| Azithromycin | Azithromycin | 46 | 42 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 46 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | suppressed |
| Estradiol | Estradiol | 44 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Celecoxib | Celecoxib | 43 | 16 |
| Prednisone | Prednisone | 43 | 40 |
| Baclofen | Baclofen | 42 | 12 |
| Atenolol | Atenolol | 41 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Fluconazole | Fluconazole | 40 | 19 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 26 |
| Donepezil Hcl | Donepezil Hcl | 39 | 11 |
| Valsartan | Valsartan | 39 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 27 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | 13 |
| Glipizide | Glipizide | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 29 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 19 |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Nystatin | Nystatin | 28 | 16 |
| Propranolol Hcl | Propranolol Hcl | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 20 |
| Torsemide | Torsemide | 26 | 11 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Proair Respiclick | Albuterol Sulfate | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 22 | suppressed |
| Lorazepam | Lorazepam | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 20 |
| Nitroglycerin | Nitroglycerin | 20 | 16 |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Acarbose | Acarbose | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | 11 |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Dutasteride | Dutasteride | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Testosterone | Testosterone | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Lasix | Furosemide | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $570.89 · 41 records | ABBVIE INC. | AIRSUPRA, ELIQUIS, FARXIGA, Korlym, MOUNJARO, NURTEC ODT, PAXLOVID, QULIPTA, REXULTI, UBRELVY, VIVITROL, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error